

# Urinary Incontinence

Dr. Fadi Sawaqed

Associate professor

Functional and Neuro-Urology

# Definition of Urinary Incontinence

**“The involuntary loss of urine  
which is objectively demonstrable  
and a social or hygienic problem.”**

\* The International Continence Society

# URINARY INCONTINENCE



Common

Treatable


Significant Effect on  
Quality of Life (QoL)

# Prevalence

- Community: 17% older men, up to 30% older women
- Hospital: up to 50% older men and women



# Prevalence of Incontinence in Women



# Aging Changes

- Decreased bladder capacity
- Reduced voiding volume
- Reduced flow rates
- Increased urine production at night


\* Nordling, J Experimental Gerontology, 2002, 37:991



# Reversible causes of UI

- **Delirium or Drugs**
- **Restricted mobility**
- **Infection, impaction**
- **Polyuria**





**Stress**

**Overflow**

**CAUSES OF  
PERSISTANT  
UI**

**Urge/OAB**



**Functional**



# Urge UI

Abrams P et al. *Urology*. 2003;61:37-49. Ouslander J. *N Engl J Med*. 2004;350(8):786-799.

The complaint of involuntary leakage accompanied by or immediately preceded by urgency




# Overactive bladder

- Includes urinary urgency with or without urge incontinence, urinary frequency, and nocturia
- Associated with involuntary contractions of the detrusor muscle

# Stress UI

Abrams P et al. *Urology*. 2003;61:37-49



The complaint of involuntary leakage with effort or exertion or on sneezing or coughing



# Mixed UI



Abrams P et al. *Urology*. 2003;61:37-49. Chaliha C et al. *Urology*. 2004;63:51-57

The complaint of involuntary leakage associated with urgency and also with exertion, effort, sneezing, or coughing




# Overflow

- Urethral blockage
- The Bladder is not able to empty properly



**Neurogenic/Atonic**



**Obstruction**

# Functional Incontinence

- Immobility
- Diminished vision
- Aphasia
- Environment
- Psychological

# Basic Evaluation of UI

- History: Type, Frequency, Severity, Bladder diary
- Physical examination, especially Genitourinary and Neurological
- Bladder stress test
- Postvoid residual
- Urinalysis, urine culture if indicated
- BUN, creatinine, fasting glucose

# Office Evaluation of UI

- Identify presence of UI
- Assess for reversible causes and treat
- If UI persistent, determine type and initiate treatment
- Identify patient who needs further evaluation and referral




# Referral Criteria


- ✓ Recurrent urinary tract infections
- ✓ Hematuria
- ✓ Elevated postvoid residual or other evidence of possible obstruction
- ✓ Recent gynecological or urological surgery or pelvic radiation
- ✓ Failed treatment of stress or urge UI

# Treatment Options

- Behavioral
- Pharmacological
- Functional Electrical Stimulation
- Surgery



# Behavioral Treatments for UI



# Self Management

- **Fluid Intake**

- Don't reduce amount
- Do not drink fluids 2 hr before bedtime
- Avoid: caffeine, alcohol, nicotine



# Timed/Scheduled Voiding

- Scheduled voiding with systematic delay of voiding
  - Schedule based on time interval pt can manage in daytime
  - Void at scheduled time even if urge not present; suppress urge if not time with “Quick Kegels”
  - Increase voiding interval by 30 min each week until continent for up to 4 hr

# Pelvic Muscle Exercises

- Isolation of the pelvic muscles
- Avoidance of abdominal, buttock or thigh muscle contractions
- Moderate repetitions of strongest contraction possible
- Ability to hold contraction 10 seconds, repeat in groups of 10-30 TID

# Medical Treatment for UI: What Works

- **Stress UI**

- Alpha adrenergic agents?

- Estrogen?

- Combination therapy?



# Alpha Adrenergic Drugs

- Phenylpropanolamine
  - Once a first line drug
  - 8 randomized controlled trials
  - Study duration: 2-6 weeks
  - % cure: 0-14
  - % side effects: 5-33%
  - **WITHDRAWN FROM MARKET** due to report of hemorrhagic stroke



# Duloxetine (Cymbalta)

- FDA application for stress UI withdrawn
- Warning for liver dysfunction, alcohol


# Estrogen

- Combined study with Phenylpropanolamine suggested improvement in combination
- Improves urogenital atrophy
- Heart and Estrogen/Progestin Replacement Study 2001: 4 yr, randomized trial, 2763 postmenopausal women <80 given combined HRT or placebo for ischemic heart disease.
  - 55% had >1 episode UI/week
  - HRT group had worsening stress and urge UI sx

# Surgery and procedures for stress incontinence

- Colposuspension. Colposuspension involves making a cut in your lower tummy (abdomen), lifting the neck of your bladder, and stitching it in this lifted position. ...
- Sling surgery. ...
- Vaginal mesh surgery (tape surgery) ...
- Urethral bulking agents. ...
- Artificial urinary sphincter.

# Surgery and procedures for stress incontinence



- (A) Stress urinary incontinence: Urine loss while coughing, sneezing or during physical activities (sports).
- (B) TVT surgery: A tape is inserted vaginally around the urethra and retropubically positioned behind the pubic bone.
- (C) Colposuspension: The loose approximation of the lateral edges of the vaginal wall to Cooper's ligament results in a hammock-like suspension of the urethra to the anterior vaginal wall (according to Burch).
- (D) Intraurethral injection of the polyacrylamide hydrogel (PAHG) into the midurethra results in the coaptation of the urethra.
- (E) Vaginal pessary (RECA fem<sup>®</sup>): Continence by pessary insertion.
- (F) TOT: A tape is inserted vaginally around the urethra and positioned by the transobturator approach along both sides of the pubic bone.

# Medical Treatment of Overactive Bladder

- **Anticholinergic Drugs** are mainstay
  - Oxybutynin IR 2.5-5 mg bid-qid
  - Ditropan XL 5-20 mg daily
  - Oxytrol patch TDS 3.9 mg 2x/wk
  - Tolterodine tartrate IR 1-2 mg bid
  - Detrol LA 2-4 mg daily


## **New Drugs:**

- Trospium chloride (Sanctura) 20 mg bid
- Darifenicin (Enablex) 7.5-15 mg daily
- Solefenicin (Vesicare) 5-10 mg daily
- **Beta-AR agonists**
- **Botulinumtoxin A**



**neuromodulation**

sacral neuromodulation (SNM)



percutaneous tibial nerve stimulation (PTNS),

